Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked conscientiously but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last few shares. The first CytoDyn article of mine, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely marketing image in the Uptick Newswire job interview that I came away with a bad viewpoint of the company.

Irony of irony, my poor viewpoint of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this expertise and also associated intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) plus the first brand new drug program approval ($five million), as well as royalty payments of 5 percent of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to get a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple indications and multiple therapies, it has this single therapies in addition to a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications in addition to multiple presentations.

Could it all be smoke cigarettes and mirrors? That’s a question I’ve been asking myself from the really beginning of the interest of mine in this particular organization. Judging with the multiples of thousands of several remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this question.

CytoDyn is a traditional battleground, or perhaps some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *